| Primary information |
|---|
| sequence ID | Seq_5554 |
| Peptide sequence | NDGARGSDGQPGPPGppGT |
| CancerPDF_ID | CancerPDF_ID3641, CancerPDF_ID3647, |
| PMID | 27026199,27026199 |
| Protein Name | Collagen alpha-1(III) chain,Collagen alpha-1(III) chain |
| UniprotKB Entry Name | CO3A1_HUMAN,CO3A1_HUMAN |
| Fluid | Urine,Urine |
| M/Z | NA,NA |
| Charge | NA,NA |
| Mass (in Da) | NA,NA |
| fdr | 1764.8,1764.8 |
| Profiling Technique | "CE-MS, Micro-TOF-MS","CE-MS, Micro-TOF-MS" |
| Peptide Identification technique | MS-MS,MS-MS |
| Quantification Technique | NA,NA |
| Labelled/Label Free | Label Free,Label Free |
| FDR | NA,NA |
| CancerPDF_ID | CancerPDF_ID3641, CancerPDF_ID3647, |
| p-Value | less than 0.05,less than 0.01 |
| Software | Proteome Discoverer 1.2,Proteome Discoverer 1.2 |
| Length | 19,19 |
| Cancer Type | Bladder cancer,Bladder cancer |
| Database | Uniprot Human non-redundant Database,Uniprot Human non-redundant Database |
| Modification | p:Hydroxy-Proline,p:Hydroxy-Proline |
| Number of Patients | 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls), 425 for training(109 patients with Recurrent UBC cases and 316 negative for recurrence controls) and 211 for validation (55 UBC recurrent cases and 156 recurrent controls) |
| Regulation | Differentially expressed between recurrence of UBC vs recurrence control,Differentially expressed between recurrence of UBC vs recurrence control |
| Validation | Independent Validation,Independent Validation |
| Sensitivity | For testing dataset 88%,For testing dataset 88% |
| Specificity | For testing dataset 51%,For testing dataset 51% |
| Accuracy | NA,NA |
| Peptide Atlas | NA |
| IEDB | |